GlassScriptPhysician profile
Anna A Patel
NPI 1255405627
$6,381.32
in general payments reported to CMS, 2019-2025
30 companies · $3,301 in 2025
The $3,301 reported for 2025 was more than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $74.18 · 2021: $325 · 2022: $400 · 2023: $415 · 2024: $1,701 · 2025: $3,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,401 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,400.83 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,343.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $954.73 | 2024-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $648.71 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $508.46 | 2021-2025 | Xifaxan, Plenvu, Relistor |
| Janssen Biotech, INC. | $400.18 | 2024-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $316.06 | 2024-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $315.48 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $271.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $270.89 | 2025 | |
| Pfizer INC. | $210.91 | 2024-2025 | |
| Ardelyx, INC. | $186.35 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $155.97 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $104.98 | 2024-2025 | Omvoh |
| Merit Medical Systems INC | $102.92 | 2025 | Endomaxx Stent and Delivery System, Esophyx |
| Regeneron Healthcare Solutions, INC. | $80.44 | 2024-2025 | Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $68.85 | 2024-2025 | Livmarli |
| Intercept Pharmaceuticals, INC. | $56.41 | 2022-2025 | |
| Celltrion USA INC. | $47.66 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $46.63 | 2025 | Injectafer |
| Novo Nordisk INC | $43.27 | 2025 | Wegovy |
| Vivus LLC | $40.92 | 2025 | Qsymia, Pancreaze |
| Braintree Laboratories, INC. | $36.81 | 2024 | Sutab, Suflave |
| Evoke Pharma, INC. | $28.65 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $27.35 | 2025 | Sutab |
| Medtronic, INC. | $21.59 | 2024 | Gi Genius |
| Nestle Healthcare Nutrition INC. | $21.41 | 2023 | |
| Biocon Biologics INC | $20.55 | 2025 | Yesintek |
| Abbott Laboratories | $18.28 | 2021 | |
| Dentsply Ih Ab | $16.51 | 2024 | Navina Rectal Catheter Set Regular |
| Echosens North America, INC. | $15.44 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.